Connor, Clark & Lunn Investment Management Ltd. Harmony Biosciences Holdings, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 8,974 shares of HRMY stock, worth $305,654. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,974Holding current value
$305,654% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding HRMY
# of Institutions
242Shares Held
45.1MCall Options Held
108KPut Options Held
49.2K-
Valor Management LLC Chicago, IL11.2MShares$382 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$199 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$118 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.61MShares$88.8 Million15.24% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.93MShares$65.7 Million0.18% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $2.02B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...